Arne Skerra

ESTP Congress


Dr. Arne Skerra is Full Professor at the Technical University of Munich in the School of Life Sciences. He started his scientific career in the field of protein engineering, where he pioneered the biosynthesis of functional antibody fragments in E. coli. Apart from several other contributions to this area, including the development of the Strep-tag technology for recombinant protein purification, and PASylation technology to extend in vivo half-life of therapeutic proteins and peptides, he invented Anticalin proteins as an alternative to antibodies. In 2001, he founded Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) to commercially exploit and clinically develop Anticalin® drug candidates.